Psyence Biomedical (Psyence Biomedical) COGS-to-Revenue : 0.00 (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical COGS-to-Revenue?

Psyence Biomedical's Cost of Goods Sold for the six months ended in Mar. 2023 was $0.00 Mil. Its Revenue for the six months ended in Mar. 2023 was $0.00 Mil.

Psyence Biomedical's COGS to Revenue for the six months ended in Mar. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Psyence Biomedical's Gross Margin % for the six months ended in Mar. 2023 was N/A%.

Psyence Biomedical COGS-to-Revenue Historical Data

The historical data trend for Psyence Biomedical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical COGS-to-Revenue Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

COGS-to-Revenue

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
COGS-to-Revenue	-	-	-

Psyence Biomedical COGS-to-Revenue Calculation

Psyence Biomedical's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Psyence Biomedical's COGS to Revenue for the quarter that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Psyence Biomedical (NAS:PBM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Psyence Biomedical's Gross Margin % for the six months ended in Mar. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Psyence Biomedical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024